Our Principal, Yolanda Wang, just returned from the 1st China Pharmaceutical Innovation Conference (CPIC 2026) in Shanghai, held from July 22–24!

It was a pleasure to attend CPIC 2026 together with fellow HKBMIA members and connect with biotech innovators from around the world. Many thanks to HKBMIA for the invitation and the opportunity to engage with industry partners. Hong Kong continues to play an important role in connecting Mainland China with the global life sciences community.

Bringing together over 10,000 participants, CPIC highlighted the strong momentum behind cross-border biopharma innovation and collaboration. It was great to see so many discussions focused on advancing healthcare innovation and building new partnerships across borders. The strong presence of AI-related healthcare and drug development initiatives was particularly impressive and reflected the rapid evolution of China’s innovation ecosystem. As IP professionals, we are reminded of the important role that IP plays in supporting innovation and bringing new technologies to market.

我們過去活動

Jennifer Che and Pauli Wong Co-Teach Advanced Patent Skills Seminar at HKU-TEC

2026年10月15日

Pauli Wong gave a talk at Hong Kong Life Sciences Society (HKLSS)

2026年10月10日

BioHK2026 | Biotech IP in practice

2026年9月16日

Jennifer Che Once Again Named to the IAM Strategy 300

2026年8月21日

Pauli Wong as a Guest speaker for “Entrepreneurial Workshop” in Poly U

2026年6月16日

Eagle IP Recognized as Top Tier Firm (Tier 1) for Patent Prosecution in IP Stars 2026 Patent Firms Ranking List

2026年6月5日

Recommended Insights

What Kind of Damage Awards Can You Get in China?

2022年6月16日
Is it worth filing for a patent in China? What kind of damage awards can you get? Pharma companies care more about injunction than damage awards, since it’s quite unlikely that any damage award can compensate for the large amounts of money that may be lost for patent infringement. Chinese courts often issue injunctions in […]
閱讀更多 >

China Announcing More Proposed Amendments to the Examination Guidelines in 2022

2022年11月17日
It’s been a year and a half since the new Chinese Patent Law came into effect (1 June 2021). Although various versions of draft Examination Guidelines have been released, thus far no official finalized versions have been confirmed. On October 31, 2022, yet another new list of proposed amendments was published1, this time consolidating the […]
閱讀更多 >

Major and Exciting Changes to China’s Patent Law [Fourth Amendment to China's Patent Law]

2019年2月20日
Major changes are on the horizon for China’s Patent Law, which will see an overhaul in many areas as early as this year (2019). On January 4, 2019, the National People’s Congress in China published the latest draft of the Fourth Amendment to China’s Patent Law. Several draft amendments have been released for public comment […]
閱讀更多 >

Beijing IP Court Reverses CNIPA Decision and Upholds Ozempic® semaglutide patent in China as VALID based on Novo Nordisk’s Post Filing Data

2024年6月27日
Recently, all eyes have been on China as the fundamental patent covering semaglutide, the active ingredient in Ozempic® and Wegovy®, will expire on March 20, 2026. It goes without saying that generics are ramping up bigtime in China (and also around the world), preparing to manufacture and sell this blockbuster drug to one of the […]
閱讀更多 >
Top crossarrow-right